ATE285764T1 - Rivastigmine zur behandlung von augenerkrankungen - Google Patents

Rivastigmine zur behandlung von augenerkrankungen

Info

Publication number
ATE285764T1
ATE285764T1 AT00992430T AT00992430T ATE285764T1 AT E285764 T1 ATE285764 T1 AT E285764T1 AT 00992430 T AT00992430 T AT 00992430T AT 00992430 T AT00992430 T AT 00992430T AT E285764 T1 ATE285764 T1 AT E285764T1
Authority
AT
Austria
Prior art keywords
rivastigmine
treatment
eye diseases
diseases
eye
Prior art date
Application number
AT00992430T
Other languages
German (de)
English (en)
Inventor
David Goldblum
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE285764T1 publication Critical patent/ATE285764T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00992430T 1999-10-19 2000-10-17 Rivastigmine zur behandlung von augenerkrankungen ATE285764T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99120678 1999-10-19
PCT/EP2000/010234 WO2001028553A1 (en) 1999-10-19 2000-10-17 Rivastigmine for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
ATE285764T1 true ATE285764T1 (de) 2005-01-15

Family

ID=8239225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00992430T ATE285764T1 (de) 1999-10-19 2000-10-17 Rivastigmine zur behandlung von augenerkrankungen

Country Status (13)

Country Link
US (2) US6534541B1 (enExample)
EP (1) EP1225890B1 (enExample)
JP (1) JP2003512324A (enExample)
AR (1) AR026062A1 (enExample)
AT (1) ATE285764T1 (enExample)
AU (1) AU766001B2 (enExample)
CA (1) CA2384690C (enExample)
DE (1) DE60017174T2 (enExample)
DK (1) DK1225890T3 (enExample)
ES (1) ES2234708T3 (enExample)
NZ (1) NZ518164A (enExample)
PT (1) PT1225890E (enExample)
WO (1) WO2001028553A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237163T3 (es) 1998-10-01 2005-07-16 Novartis Ag Nuevas formulaciones orales de revastigmina de liberacion controlada.
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
CN107417574B (zh) * 2017-03-21 2019-12-03 浙江省医学科学院 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US4900748A (en) 1988-03-04 1990-02-13 The United States Of America As Represented By The Department Of Health And Human Services Carbamates related to (-)-physostigmine as cholinergic agents
JP3708957B2 (ja) 1991-09-26 2005-10-19 アメリカ合衆国 (−)−エゼロリン、(−)−n1−ノルエゼロリンおよび(−)−n1−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩:特異的アセチルコリンエステラーゼ阻害薬としての使用
ES2206449T3 (es) 1991-09-26 2004-05-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Inhibidores de colinesterasas, composiciones farmaceuticas y sus usos.
AU1138097A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of prostaglandins and miotics for lowering intraocular pressure

Also Published As

Publication number Publication date
ES2234708T3 (es) 2005-07-01
US6835748B2 (en) 2004-12-28
PT1225890E (pt) 2005-05-31
JP2003512324A (ja) 2003-04-02
AR026062A1 (es) 2002-12-26
NZ518164A (en) 2003-10-31
EP1225890B1 (en) 2004-12-29
DK1225890T3 (da) 2005-04-04
WO2001028553A1 (en) 2001-04-26
DE60017174T2 (de) 2005-12-22
US20030119832A1 (en) 2003-06-26
US6534541B1 (en) 2003-03-18
AU2834901A (en) 2001-04-30
CA2384690C (en) 2010-08-17
DE60017174D1 (de) 2005-02-03
EP1225890A1 (en) 2002-07-31
AU766001B2 (en) 2003-10-09
CA2384690A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EP1117431A4 (en) TREATMENT OF ACIDOSIS
DE69737067D1 (de) Vakzine zur behandlung von mycosen
EP1239851A4 (en) TREATMENT OF HYPERPROLIFERATIVE DISORDERS
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1225890

Country of ref document: EP